ABL Bio
Pioneering bispecific antibodies for oncology and neurodegenerative diseases
Seongnam, South Korea · Founded 2016
- Headquarters
- Seongnam
- Employees
- 51–200
- Founded
- 2016
- Business Model
- B2B
- Website
- ablbio.com
About
ABL Bio is a South Korean research-led biotechnology company and pioneer in bispecific antibodies, with programs spanning immuno-oncology, neurodegenerative diseases, and antibody-drug conjugates. Founded in 2016 by Sang Hoon Lee and listed on the KOSDAQ exchange (298380), the company develops novel therapeutic platforms that address high unmet medical needs by combining bispecific antibody expertise with innovative drug delivery approaches. ABL Bio collaborates with global partners to advance its pipeline — which includes programs such as ABL301 for Parkinson's disease and ABL503 for solid tumors — and in 2025 established NEOK Bio in California with $75 million from Blackstone Life Sciences to advance two bispecific ADCs in the US market.
Summary
ABL Bio is a Biotech company based in Seongnam, South Korea, founded in 2016.
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company